Phase II trial of irinotecan plus s-1 (IRIS) with cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS wild-type metastatic colorectal cancer (mCRC): HGCSG0902-Comparison of administration interval in cetuximab treatment.

被引：0

作者：

Komatsu, Yoshito

Yuki, Satoshi

Nakatsumi, Hiroshi

Hosokawa, Ayumu

Nakamura, Michio

Muto, Osamu

Meguro, Takashi

Iwanaga, Ichiro

Hatanaka, Kazuteru

Tsuji, Yasushi

Sato, Atsushi

Eto, Kazunori

Furukawa, Kouichi

Onodera, Manabu

Tateyama, Miki

Takahashi, Yasuo

Dazai, Masayoshi

Yokoyama, Sachio

Honda, Takuya

Sakata, Yuh

机构：

[1] Hokkaido Univ Hosp, Ctr Canc, Dept Canc Chemotherapy, Sapporo, Hokkaido 060, Japan

[2] Hokkaido Univ Hosp, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido 060, Japan

[3] Toyama Univ, Fac Med, Dept Gastroenterol & Hematol, Toyama 930, Japan

[4] Sapporo City Gen Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan

[5] Japanese Red Cross Akita Hosp, Dept Med Oncol, Akita, Japan

[6] Hokkaido Gastroenterol Hosp, Sapporo, Hokkaido, Japan

[7] Japanese Red Cross Kitami Hosp, Dept Gastroenterol, Kitami, Hokkaido, Japan

[8] Hakodate Municipal Hosp, Dept Gastroenterol, Hakodate, Hokkaido, Japan

[9] Tonan Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[10] Hirosaki Univ, Grad Sch Med, Dept Med Oncol, Hirosaki, Aomori, Japan

[11] Tomakomai City Hosp, Dept Gastroenterol, Tomakomai, Japan

[12] Niigata City Gen Hosp, Niigata, Japan

[13] Abashiri Kosei Gen Hosp, Dept Gastroenterol, Abashiri, Japan

[14] Tomakomai Nisshou Hosp, Dept Internal Med, Tomakomai, Japan

[15] Hokkaido Canc Ctr, Dept Gastroenterol, Sapporo, Hokkaido, Japan

[16] Kushiro Rosai Hosp, Dept Internal Med, Kushiro, Hokkaido, Japan

[17] Kumamoto City Hosp, Dept Surg, Kumamoto, Japan

[18] Nagasaki Univ, Dept Gastroenterol & Hepatol, Grad Sch Biomed Sci, Nagasaki 852, Japan

[19] Misawa City Hosp, Misawa, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期

关键词：

D O I：

10.1200/jco.2015.33.3_suppl.746

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

746

引用

页数：1

共 50 条

[31] CANADIAN ECONOMIC ANALYSIS OF BEVACIZUMAB, CETUXIMAB, AND PANITUMUMAB IN THE FIRST LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC)
Lawrence, D.
Maschio, M.
Yunger, S.
Easaw, J.
Aucoin, N.
Weinstein, M.
ANNALS OF ONCOLOGY, 2012, 23 : 202 - 202
[32] Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer
Shitara, Kohei
Ura, Takashi
Matsuo, Keitaro
Takahari, Daisuke
Yokota, Tomoya
Yuki, Satoshi
Yoshida, Motoki
Utsunomiya, Setsuo
Sato, Yozo
Yamaura, Hidekazu
Kato, Mina
Inaba, Yoshitaka
Tajika, Masahiro
Kawai, Hiroki
Yamazaki, Kentaro
Komatsu, Yoshito
Muro, Kei
EUROPEAN JOURNAL OF CANCER, 2011, 47 (18) : 2673 - 2680
[33] A phase II trial of high-dose cetuximab (cmab) plus irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (MCRC) who progressed on standard-dose cmab plus irinotecan
Patta, A. M.
McMahon, J. A.
Samborski, C.
Fakih, M.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[34] Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status
Myoung Joo Kang
Yong Sang Hong
Kyu-pyo Kim
Sun Young Kim
Ji Yeon Baek
Min-Hee Ryu
Jae-Lyun Lee
Heung Moon Chang
Mi-Jung Kim
Hee Jin Chang
Yoon-Koo Kang
Tae Won Kim
Investigational New Drugs, 2012, 30 : 1607 - 1613
[35] Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status
Kang, Myoung Joo
Hong, Yong Sang
Kim, Kyu-pyo
Kim, Sun Young
Baek, Ji Yeon
Ryu, Min-Hee
Lee, Jae-Lyun
Chang, Heung Moon
Kim, Mi-Jung
Chang, Hee Jin
Kang, Yoon-Koo
Kim, Tae Won
INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1607 - 1613
[36] E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).
Hochster, Howard S.
Catalano, Paul J.
Mitchell, Edith P.
Cohen, Deirdre Jill
O'Dwyer, Peter J.
Benson, Al Bowen
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[37] Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
Toshiki Masuishi
Akihito Tsuji
Masahito Kotaka
Masato Nakamura
Mitsugu Kochi
Akinori Takagane
Ken Shimada
Tadamichi Denda
Yoshihiko Segawa
Hiroaki Tanioka
Hiroki Hara
Tamotsu Sagawa
Takanori Watanabe
Takao Takahashi
Yuji Negoro
Dai Manaka
Hideto Fujita
Takeshi Suto
Masahiro Takeuchi
Wataru Ichikawa
Masashi Fujii
British Journal of Cancer, 2020, 123 : 1490 - 1495
[38] Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer
Zekri, Jamal
Baghdadi, Mohammed Abbas
Ibrahim, Refaei Belal
Meliti, Abdelrazak
Sobahy, Turki M.
ECANCERMEDICALSCIENCE, 2022, 16 : 1 - 16
[39] Rechallenge with cetuximab 1 irinotecan in 3rd-line in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients with
Daniele, Rossini
Daniele, Santini
Chiara, Cremolini
Lisa, Salvatore
Sara, Lonardi
Emanuela, Dell' Aquila
Giuseppe, Aprile
Fotios, Loupakis
Bruno, Vincenzi
Francesca, Battaglin
Vanessa, Buoro
Emiliano, Tamburini
Deborah, Basile
Domenico, Corsi
Iacopo, Fioroni
Gianluca, Masi
Carlotta, Antoniotti
Beatrice, Borelli
Marzia, Del Re
Giuseppe, Tonini
Alfredo, Falcone
ANNALS OF ONCOLOGY, 2017, 28
[40] A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan
Fora, Ahmad A.
McMahon, Jeanne A.
Wilding, Greg
Groman, Adrienne
Ma, Wen Wee
Romano, Karen S.
Fakih, Marwan G.
ONCOLOGY, 2013, 84 (04) : 210 - 213

← 1 2 3 4 5 →